38 APIs are now being manufactured in India

8 August 2023

The Indian pharmaceutical industry has made significant progress in reducing its dependency on China for active pharmaceutical ingredients (APIs). Some 38 APIs, which were previously heavily dependent on imports, are now being produced domestically.

Health minister Mandaviya pointed out that the Doklam conflict of 2017, (the China-India border standoff), provided the impetus for a self-reliant strategy. India was forced to reassess its dependence on a single source for 95% of APIs used in formulations.

In February 2020, when the world was battling Covid, Indian government officials drafted a list of 38 raw materials they intended to produce locally to reduce dependency on Chinese imports.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK